= Aim of the Study: This open-label randomized controlled trial (RCT) aims to assess the
effectiveness and safety of oral bisoprolol in treating atrial fibrillation (AF) with
rapid ventricular response (RVR) and atrial flutter within an acute ED setting. We aim to
determine the viability of utilizing oral bisoprolol as a primary treatment option for
atrial fibrillation with rapid ventricular response (RVR) and atrial flutter by
evaluating its clinical outcomes, focusing on rate control and potential adverse effects,
and comparing them with those of intravenous diltiazem. The findings from this research
will enhance our understanding and guide clinicians towards evidence-based therapeutic
decisions, ensuring optimal patient care and improved outcomes.
= Research Objectives and Hypothesis: The research aims to test the null hypothesis,
which posits that there is no significant difference in achieving a heart rate (HR) below
110 beats/min or a reduction in ventricular rate by at least 20% between the oral
bisoprolol (PO) and intravenous diltiazem (IV) groups after 60 minutes.
= Study Design: This is a prospective, open-label, randomized controlled trial that will
be conducted as a single-center investigation within the Emergency Department of Sultan
Qaboos University Hospital (SQUH). This study will involve adult patients aged 18 and
older, and all eligible participants will be given written informed consent to join the
research.
= Control Group: Participants in this group will be administered a single intravenous
dose of diltiazem at a dosage of 0.25 mg/kg, with a maximum dose capped at 30 mg.
= Intervention Group: Participants in this group will receive a single oral dose of
bisoprolol, set at a dosage of 5 mg, with a maximum dose limit of 5 mg.
Primary Endpoints:
The primary efficacy outcome evaluated by achieving a HR < 110 beats per minute
or a decrease ≥20% of baseline HR at 60 minutes.
The primary safety outcome measures were HR < 60 bpm and SBP < 95 mm Hg.
Secondary Endpoints:
The use of rescue medication (Rescue rate control defined as the administration
of a supplementary rate control medication after 60 minutes of the initial dose
of the interventional drug).
Proportion of patients who required hospitalization (hospital admission/ICU
admission).
ED revisit.
Treatment-related adverse events.
Dizziness, headaches, gastrointestinal symptoms.
Worsening of heart failure or pulmonary edema.
Sample Size:
In addressing the novel concept of comparing the effectiveness of oral bisoprolol versus
IV diltiazem in treating AF or atrial flutter with RVR in an acute setting, we aim to
conduct a pilot study with 30 patients in each group to calculate the study sample size.
Study Procedures:
Present to the Clinical Site:
- An eligible adult patient aged 18 years or older, who presents with
symptomatic rapid ventricular response atrial fibrillation or atrial
flutter and requires treatment for rate control.
Eligibility Assessments:
- Inclusion and exclusion criteria will be checked.
Informed Consent:
- Potentially eligible participants will be identified by their treating
clinicians. Written informed consent to participate in this study will
follow a process of information exchange between clinicians and potential
participants.
Study the Effectiveness in Achieving Rate Control:
Data will be collected prospectively, including demographics, medical
history, vital signs, and ECG results. Each patient will be promptly
assessed, and continuous monitoring will be established for every patient
to monitor cardiac rhythm, heart rate (HR), blood pressure, and oxygen
saturation levels.
Heart rate will be recorded every 15 mins till the 90-minute mark.
For the therapy to be considered effective, the patients had to achieve a
ventricular rate ≤110/min or experience a drop in ventricular rate of at
least 20% at 60 minutes.
12-lead ECG will be done every 30 minutes at 0, 30, and 60 minutes.
Relevant secondary outcomes will be recorded.
Standard-of-Care Procedures:
- Patients may receive additional medications as part of their emergency
department treatment after 60 minutes if they remain hemodynamically
stable. Any additional medications administered will be recorded. The need
for additional medications (including the drug administered, the dose, the
time, and the route of administration) will be recorded.
Safety Assessments:
All adverse events will be documented on the adverse event case log.
Serious adverse events should be immediately reported to the primary
investigator. Any serious adverse event will be reported immediately to
the Institutional Review Board. An adverse event is considered serious if
it causes a threat to the patient's life or functioning. The U.S. Food and
Drug Administration (FDA) defines a serious adverse event (SAE) as any
untoward medical occurrence that:
Results in death.
Is life-threatening (places the patient at risk of death).
Requires hospitalization or prolongs an existing hospitalization.
Causes persistent or significant disability or incapacity.
Requires medical intervention to prevent one of the above outcomes.
Follow-Up:
- All participants will be followed up after 24 hours and 48 hours.
Risks and Benefits:
Bisoprolol, a cardioselective beta-1 adrenergic agent, is recognized for its potency and
the convenience of once-daily dosing. It is well-tolerated and deemed suitable for
patients with chronic bronchoconstrictive disease, with safety established through
clinical trials. On the other hand, diltiazem, a calcium channel blocker, is commonly
used for hypertension and short-term AF management due to its rapid onset and lower
impact on blood pressure, making it suitable for emergencies.
In collaboration with cardiology experts, the designated 60-minute time frame has been
established to balance clinical relevance with patient safety. The administration of oral
bisoprolol is considered a reliable and convenient treatment modality, assumed to be
fast, painless, and associated with a lower risk of complications. This approach aims to
facilitate a smooth transition to oral maintenance and provide an alternative for AF
management in a busy Emergency Department. Meanwhile, intravenous (IV) diltiazem is
acknowledged for its rapid onset, rendering it effective for the treatment of symptomatic
atrial fibrillation patients in the emergency department. Throughout the ED phase, each
patient will undergo close monitoring to ensure their utmost safety.
It is crucial to carefully consider the balance between potential benefits and risks,
particularly in cases involving heart failure patients. Detailed monitoring protocols are
in place to swiftly detect and manage any adverse effects or complications that may
arise. Our preemptive strategies include comprehensive and regular patient monitoring,
the implementation of an emergency protocol to address unexpected issues, and a
meticulous medication review prior to any treatment administration. We are committed to
transparent and ongoing communication with all study participants, maintaining a
continuous focus on safeguarding their health and ensuring that the potential advantages
of participation outweigh the risks.